Table 3.
Comparison of Baseline Characteristics Among Black Participants Within Each Estimated Glomerular Filtration Rate (eGFR) Category by Reclassification Status after Adoption of the Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration eGFR Creatinine Equation
| Variable | Participants by eGFR Stage, %a | |||||||
|---|---|---|---|---|---|---|---|---|
| Stage 1: No Change (n = 18 141) | Stage 1 → 2 (n = 4170) |
Stage 2: No Change (n = 6566) | Stage 2 → 3 (n = 733) |
Stage 3: No Change (n = 1394) |
Stage 3 → 4 (n = 55) |
Stage 4: No Change (n = 220) |
Stage 4 → 5 (n = 19) |
|
| Death during study | 11 | 12 | 17 | 23 | 32 | 49 | 44 | 53 |
| Age, mean (SD), y | 41 (11) | 46 (10) | 50 (10) | 52 (10) | 55 (11) | 54 (12) | 52 (12) | 55 (10) |
| Hypertension | 21 | 30 | 40 | 55 | 65 | 78 | 71 | 95 |
| HCV positive | 17 | 19 | 23 | 27 | 26 | 18 | 27 | 47 |
| Diabetes | 7 | 8 | 11 | 17 | 21 | 35 | 22 | 37 |
| CVD | 3 | 4 | 6 | 9 | 12 | 16 | 14 | 26 |
| MI | 1 | 1 | 2 | 4 | 4 | 7 | 4 | 5 |
| CAD (non-MI) | 2 | 3 | 4 | 6 | 8 | 11 | 9 | 26 |
| CVA | 1 | 1 | 1 | 2 | 3 | 6 | 4 | 0 |
| PVD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TIA | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 |
| Vasculitis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| History of AIDS | 15 | 15 | 16 | 23 | 22 | 24 | 21 | 37 |
Abbreviations: CAD, coronary artery disease; CKD-EPI Chronic Kidney Disease Epidemiology Collaboration; CVA, cerebrovascular accident; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; MI, myocardial infarction; PVD, peripheral vascular disease; SD, standard deviation; TIA, transient ischemic attack.
Data represent percentage of participants unless otherwise specified. Arrows indicate reclassification to another eGFR stage. The stages were defined as follows: stage 1, eGFR ≥90 mL/min/1.73 m2; stage 2, 60–89 mL/min/1.73 m2; stage 3, 30–59 mL/min/1.73 m2; stage 4, 15–29 mL/min/1.73 m2; and stage 5, <15 mL/min/1.73 m2.